B cell strategy to maintain remission in ANCA-associated vasculitides?

Journal of Rheumatology

Volumn 39, Issue 1, 2012, Pages 4-5

  Adler, Sabine ^a,b   Villiger, Peter M ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD19 ANTIGEN; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; B LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA A (H1N1); MICROSCOPIC POLYANGIITIS; MULTIPLE CYCLE TREATMENT; OTITIS MEDIA; PRIORITY JOURNAL; RELAPSE; REMISSION; SKIN ABSCESS; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROSCOPIC POLYANGIITIS; VASCULITIS, CENTRAL NERVOUS SYSTEM; WEGENER GRANULOMATOSIS;

EID: 84855384962     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111313     Document Type: Editorial

References (14)

1. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803.
2. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis - a systematic review. JAMA 2007;298:655-69. (Pubitemid 47236417)
3. Wilde B, van Paassen P, Witzke O, Tervaert JW. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011;79:559-612.
4. Hewins P, Tervaert JW, Savage CO, Kallenberg CG. Is Wegener's granulomatosis an autoimmune disease? Curr Opin Rheumatol 2000;12:3-10. (Pubitemid 30036681)
5. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-40. (Pubitemid 34016203)
6. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
7. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
8. US Food and Drug Administration press announcement April 19, 2011. [Internet. Accessed November 18, 2011.] Available from: http://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm251946.htm
9. Specks U, Stone JH. Long-term efficacy and safety results of the RAVE trial. Clin Exp Immunol 2011;164 Suppl 1:50-67.
10. Rhee EP, Laliberte KA, Niles J. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394-1400.
11. Jones RB, Smith R, Guerry MJ, Laurino S, Catapano F, Chaudhry A, et al. Protocolized versus non-protocolized RTX treatment for refractory ANCA-AAV. Clin Exp Immunol 2011;164S:58.
12. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, Grasland A, Zoulim A, Le Guen J, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012;39:125-30.
13. De la Torre I, Moura RA, Leandro MJ, Edwards J, Cambridge G. B-cell-activating factor receptor expression on naïve and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Ann Rheum Dis 2010; 69:2181-8.
14. Möller B, Aeberli D, Fuhrer M, Vajtai I, Vögelin E, Ziswiler HR, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther 2009;11:R62.